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objectives: We intended to assess the safety and efficacy of intravenous vernakalant for rapid conversion of recent-onset atrial fibrillation (ROAF).
methods: We searched PubMed, Cochrane library and Embase for studies comparing intravenous vernakalant with placebo or other antiarrhythmic 
drugs (AAD) for treatment of ROAF. Efficacy and safety outcomes measured were the rate of successful chemical cardioversion and serious adverse 
events (SAE) respectively. Random effects model with inverse variance weighting was used to calculate pooled relative risks (RR) for both outcomes.
results: In 5 RCTS and 2 observational studies (n=1161) included for analysis, 872 patients had recent onset AF. Of these 497, 229 and 146 
patients received vernakalant, anti-arrhythmic drugs (amiodarone, flecainide) and placebo respectively. When compared with controls (placebo and 
other AADs combined), vernakalant was associated with increased cardioversion rate (Risk Ratio 3.86; 95 % CI, 1.97 - 7.57; p<0.001) and similar 
SAE rate (RR 0.85; 95% CI, 0.60 -1.2; p = 0.35). The increase in cardioversion rate with vernakalant was primarily driven by its improved efficacy 
when compared with placebo (RR 8.25; 95 % CI, 3.48 - 19.55; p<0.001). There was no difference in cardioversion rate when compared with anti-
arrhythmic drugs (RR 1.83; 95 % CI, 0.99 - 3.39; p =0.054).
conclusion: Vernakalant is safe and effective for cardioversion of recent onset AF. It is clearly superior to placebo but equivalent to other AADs for 
cardioversion.
 
